Grifols
| Company type | Public |
|---|---|
| ISIN | ES0171996087 |
| Industry | Healthcare |
| Founded | 1909 |
| Headquarters | Sant Cugat del Vallès (Barcelona, Spain) |
Key people |
|
| Products | Plasma-derived medicines to treat chronic, rare and prevalent diseases, tools and services for hospitals, pharmacies and healthcare professionals. |
| Revenue | €7.2 billion (2024) |
| 157,000,000 euro (2024) | |
Number of employees | More than 23,800 (2024) |
| Website | grifols |
| Footnotes / references | |
Grifols, S.A. (Catalan: [ˈɡɾifuls]) is a global healthcare company and leading producer of plasma-derived medicines founded in Barcelona, Spain, in 1909. With a workforce of over 23,800 employees, Grifols serves more than 110 countries and regions and maintains a direct presence in over than 30.
Principally a producer of blood plasma–based products, a field in which it is the European leader and third largest worldwide, and other biopharmaceuticals, the company is also in transfusion medicine, supplying devices, instruments and reagents for clinical testing laboratories, in addition to clinical diagnostic technologies. Grifols also provides biological supplies for life-science research, clinical trials and for manufacturing pharmaceutical and diagnostic products.
Grifols is focused on four main therapeutic areas: immunology, infectious diseases, pulmonology and critical care.